Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Colorcon
Farmers Insurance
Fish and Richardson
Cipla
Harvard Business School
Accenture
Baxter
Chubb

Generated: October 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,469,012

« Back to Dashboard

Which drugs does patent 6,469,012 protect, and when does it expire?

Patent 6,469,012 protects VIAGRA and is included in one NDA.

Protection for VIAGRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-six countries.

Summary for Patent: 6,469,012
Title: Pyrazolopyrimidinones for the treatment of impotence
Abstract:The use of a compound of formula (I) ##STR1## wherein R.sup.1 is H; C.sub.1 -C.sub.3 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.6 cycloalkyl; R.sup.3 is optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 perfluoroalkyl; C.sub.3 -C.sub.5 cycloalkyl; C.sub.3 -C.sub.6 alkenyl; or C.sub.3 -C.sub.6 alkynyl; R.sup.4 is optionally substituted C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkanoyl, (hydroxy)C.sub.2 -C.sub.4 alkyl or (C.sub.2 -C.sub.3 alkoxy)C.sub.1 -C.sub.2 alkyl; CONR.sup.5 R.sup.6 ; CO.sub.2 R.sup.7 ; halo; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H or C.sub.1 -C.sub.4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group; R.sup.7 is H or C.sub.1 -C.sub.4 alkyl; R.sup.8 is optionally substituted C.sub.1 -C.sub.3 alkyl; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R.sup.12)-piperazinyl group; R.sup.11 is H; optionally substituted C.sub.1 -C.sub.3 alkyl; (hydroxy)C.sub.2 -C.sub.3 alkyl; or C.sub.1 -C.sub.4 alkanoyl; R.sup.12 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; CONR.sup.13 R.sup.14 ; CSNR.sup.13 R.sup.14 ; or C(NH)NR.sup.13 R.sup.14 ; and R?13? and R.sup.14 are each independently H; C.sub.1 -C.sub.4 alkyl; or substituted C.sub.2 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Inventor(s): Ellis; Peter (Sandwich, GB), Terrett; Nicholas Kenneth (Sandwich, GB)
Assignee: Pfizer Inc (New York, NY)
Application Number:08/549,792
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,469,012
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 6,469,012

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,469,012

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9311920Jun 09, 1993
PCT Information
PCT FiledMay 13, 1994PCT Application Number:PCT/EP94/01580
PCT Publication Date:December 22, 1994PCT Publication Number: WO94/28902

International Family Members for US Patent 6,469,012

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 163852 ➤ Try a Free Trial
Australia 676571 ➤ Try a Free Trial
Australia 6797394 ➤ Try a Free Trial
Canada 2163446 ➤ Try a Free Trial
China 1071118 ➤ Try a Free Trial
China 1124926 ➤ Try a Free Trial
China 1742731 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Teva
Cantor Fitzgerald
Julphar
Medtronic
US Army
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.